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ABSTRACT
Adult stem cell quiescence is critical to ensure re-
generation while minimizing tumorigenesis. Epige-
netic regulation contributes to cell cycle control and
differentiation, but few regulators of the chromatin
state in quiescent cells are known. Here we report
that the tumor suppressor PRDM2/RIZ, an H3K9
methyltransferase, is enriched in quiescent muscle
stem cells in vivo and controls reversible quiescence
in cultured myoblasts. We find that PRDM2 asso-
ciates with >4400 promoters in G0 myoblasts, 55% of
which are also marked with H3K9me2 and enriched
for myogenic, cell cycle and developmental regula-
tors. Knockdown of PRDM2 alters histone methyla-
tion at key promoters such as Myogenin and Cy-
clinA2 (CCNA2), and subverts the quiescence pro-
gram via global de-repression of myogenesis, and
hyper-repression of the cell cycle. Further, PRDM2
acts upstream of the repressive PRC2 complex in
G0. We identify a novel G0-specific bivalent chro-
matin domain in the CCNA2 locus. PRDM2 pro-
tein interacts with the PRC2 protein EZH2 and reg-
ulates its association with the bivalent domain in
the CCNA2 gene. Our results suggest that induc-
tion of PRDM2 in G0 ensures that two antagonis-
tic programs––myogenesis and the cell cycle––while
stalled, are poised for reactivation. Together, these
results indicate that epigenetic regulation by PRDM2
preserves key functions of the quiescent state, with
implications for stem cell self-renewal.
INTRODUCTION
Epigenetic regulatory mechanisms play a crucial role in cell
fate decisions, whereby global and local controls are im-
posed on chromatin and result in distinct transcriptional
programs. The epi-genome of pluripotent embryonic stem
cells (ESC) is highly permissive, accommodating both self-
renewal and broad differentiation potential. During devel-
opment, chromatin configuration becomes progressively re-
strictive as cells commit and differentiate into specific lin-
eages. Regulation at the level of chromatin is emerging as a
primary determinant in the establishment and maintenance
of heritable gene expression patterns (1–4).
The global chromatin landscape is controlled by a hier-
archy of mechanisms, of which regulation at the level of
the basic unit, the nucleosome, is best understood. Inter-
actions of the core nucleosomal histones (H2A, H2B, H3
and H4) leave their N terminal tails accessible to a range
of post-translational modifications that are deposited, read
or erased by a wide variety of chromatin modifying en-
zymes, altering the packaging of DNA. Dynamic changes
in histone modifications can therefore also alter DNA-
transcription factor interactions, and may either accom-
pany or precede transcriptional activation or repression.
Thus, the ‘histone code’ embodies gene regulatory infor-
mation that is embedded in complex cell type- and cell
state-specific combinations of histone modifications (5).
Typically, in addition to the requisite RNA polymerase II
(pol II) binding, transcription activation correlates with tri-
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methylation of lysine 4 of H3 (H3K4me3), together with hi-
stone acetylation (H3K9Ac). By contrast, transcription re-
pression often involves tri-methylation of lysine 27 of H3
(H3K27me3) and di-or tri-methylation of lysine 9 of H3
(H3K9me2/3), through the recruitment of repressive pro-
tein complexes.
Heritability of epigenetic information has to meet the
challenge of chromatin disassembly and reassembly dur-
ing DNA synthesis, necessitating cellular memory mecha-
nisms, particularly in adult stem cells (ASC). Adult tissues
are comprised of cells in distinct non-proliferating states
with distinct functions. In skeletal muscle, differentiated
myofibers are permanently arrested (post-mitotic), but a
rare population of satellite stem cells enters an alternate
cell cycle exit (quiescence or G0), retaining the option to
reactivate and repair damage (reviewed in (6)). Recent evi-
dence suggests that rather than a state of passive hiberna-
tion entered when nutrients or mitogens are limiting, the
quiescence program is actively regulated at transcriptional
(7–10) and epigenetic (11–13) levels. Deregulation of quies-
cence may underlie both tumorigenesis (failure to enter G0
leading to uncontrolled proliferation), as well as degenera-
tive disease (failure to exit G0 leading to loss of progenitor
function), necessitating an understanding of mechanisms
that control this arrested state.
The mechanisms by which stem cells achieve cellular
memory to keep specific regions of their genome repressed
but ready to respond to regenerative signals have been
emerging over the past decade (14,15). Although ASC ex-
hibit restricted proliferative capacity and potency in com-
parison to ESC, they also face the opposing demands of
stemness versus differentiation. When ASC are quiescent,
tissue-specific genes are repressed, yet these cells must ac-
tivate the appropriate lineage network when called upon to
regenerate damaged tissue, restoring not only functional tis-
sue but also a new reserve stem cell pool.
In muscle progenitors or myoblasts, quiescence is asso-
ciated with repression of lineage determinants both in cul-
ture (16,17) and in vivo (18).Myogenic commitment and dif-
ferentiation are controlled by the MyoD family of muscle
regulatory factors (MRFs-MyoD1, Myf5, MyoG, MRF4),
in conjunction with Mef2 (19). MyoD couples differentia-
tion to permanent arrest by inducing cell cycle inhibitors
p21 and Rb, with coordinate activation of muscle genes by
Myogenin (MyoG) (20). Quiescence, however is marked by
repression of MyoD, absence of MyoG, p21 and Rb, (16),
and induction of Rb2/p130 (21), which together block both
myogenesis and S phase entry. Thus, in G0, two antagonis-
tic global programs are reined in, but can be re-activated by
extrinsic signals.
Epigenetic changes precede and accompany myogenic
gene activation, as MRFs recruit distinct histone modi-
fiers to induce/maintain the muscle program (22,23). Dur-
ing irreversible arrest, tissue-specific and cell cycle genes
experience differential epigenetic regulation at the level of
histone modification. For example, the MyoG promoter
is activated when MyoD recruits p300 HAT, displacing
repressive HMTs EZH2 and Suv39h1 (24). However, on
cell cycle promoters, Rb and E2F4 associate with Sin3b,
HDACs and HMTs to create repressive H3K9me3 marks
(25). Rb can also recruit Polycomb complexes, which de-
posit H3K27me3 marks and permanently silence cell cycle
genes during differentiation (26). In human cells, p130 and
E2F factors associate withMuvB-like proteins in G0, form-
ing the DREAM complex that is involved in repression of
cell cycle genes (27) and in Drosophila, dREAM is impli-
cated in repression of a wide variety of developmental genes
(28).
In ESC, cell fate loci are located in ‘bivalent domains’
(marked by both H3K27me3 and H3K4me3), in a tran-
scriptionally repressed state poised for activation (29–31).
Lineage commitment correlates with a shift to uniquemark-
ing by tri-methylation of either H3K27 (silencing) or H3K4
(activation), which underlies and reinforces cell fate choices.
ASC are also thought to maintain a chromatin configura-
tion permissive to a (restricted) set of alternate fates (4).
Recent reports describe bivalent domains in ASC including
muscle SCs (32), butmechanisms of poising are unexplored.
Using genome-wide location analysis, transcriptome
analysis and RNAi, we now report that a single regulator,
an H3K9 methyl transferase PRDM2, is induced in quies-
cence and binds to thousands of promoters in quiescent my-
oblasts, over half of which are also marked by the repressive
H3K9me2 mark. PRDM2 acts in two modes on differen-
tiation versus cell cycle target genes––while it represses the
activity of theMyogenin promoter in quiescence, this epige-
netic regulator also controls association of the PRC2 com-
plex at a novel G0-specific bivalent domain in the CCNA2
gene, preventing silencing. We also present evidence that
PRDM2 is found in protein complexes containing EZH2, a
keyH3K27methyl transferase involved in silencing. Our re-
sults implicate PRDM2 in epigenetic mechanisms promot-
ing establishment and/ormaintenance of the reversibly qui-
escent state, an important feature of ASCs.
MATERIALS AND METHODS
Ethics statement
All animal experiments were performed with the approval
of the Institutional Animal Ethics Committee at inStem.
Human myoblasts were obtained with informed consent
from healthy volunteers in Denmark (see below). Human
MSC were purchased from Texas A and M, human dermal
fibroblasts were obtained from Lonza and used with the ap-
proval of the inStem Institutional Committee for Stem Cell
Research.
Cell culture
C2C12 myoblasts (obtained originally from H. Blau, Stan-
ford) were sub-cloned and maintained in growth medium
(GM; DMEM+ 20% Fetal Bovine Serum (FBS)); differen-
tiation was induced in low mitogen medium (DM: DMEM
+ 2% horse serum), for 5 days to form mature myotubes
(MT); synchronization in G0 was by suspension culture in
1.3% methylcelluose prepared in GM, as described (11,17).
Human primary myoblasts were isolated from muscle
biopsies taken from vastus lateralis of three males (18–20
years), with informed consent and approval of the local
ethics committee of Region of SouthernDenmark. Cultures
were established, arrested and differentiated as previously
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described (33), except that 10% FBS was replaced with 2%
Ultroser G (Pall), 2% FBS.
Primary human bone marrow-derived mesenchymal stem
cells (MSC) were purchased from Institute for Regenera-
tive Medicine at Scott and White, Texas A and M Health
Science Center College of Medicine at passage 1 and ex-
panded in -MEM containing 20% serum. Quiescence was
induced in hMSCs at passage 3–4 by suspension in -MEM
containing 1.3% methylcellulose with 20% serum for 48 h.
Under these conditions, MSC undergo synchronous arrest
in G0 as for human MBs (Rumman, M., Majumder, A.,
Harkness, L., Balgopal, V. Pillai, MS, Kassem, M. and J.
Dhawan, manuscript in preparation).
Primary human dermal fibroblasts:were expanded in 10%
FBS (passage 3–4), grown to 80% confluence and subjected
to serum starvation in 0.5% FBS for 48 h to induce quies-
cence and re-activated with 10% FBS for 24 h.
Mouse muscle satellite cells: primary SC were purified
from adult mice as reported by Fukada et al. (34). About
4–6 week old female C57BL/6 mice were used to isolate
muscle satellite cells. Briefly, hind limb muscle groups were
dissected out, minced and digested in collagenase Type II
(Cat# LS4196 Worthington Biochemical, 400U/ml final
concentration) for 90 min at 37◦C with gentle vortexing af-
ter every 15 min. The digested muscle slurry was filtered
through 40-m nylon mesh. The single cell suspension was
treated with 0.8% ammonium chloride to lyse RBCs. Mus-
cle mononuclear cells were washed twice with phosphate
buffered saline (PBS) and stained with biotinylated anti-
VCAM-1 (BD Biosciences, Cat#553331) primary antibody
for 30 min, washed with PBS and stained with Streptavidin,
Alexa Fluor-488 conjugate (Invitrogen, Cat#S-11223) and
CD45-PE (BD Biosciences, Cat#553081) conjugated anti-
body. Cell sorting was performed on Moflo XPD cytome-
ter using gates for the VCAM-1 positive and CD45 nega-
tive population. The gated cell population was sorted di-
rectly into Trizol for RNA isolation or into GM for subse-
quent culturing onMatrigel (BD Biosciences, Cat#354230)
coated dishes.
Single muscle fiber analysis
Single skeletal muscle fibers were isolated from the hind
limb muscle groups-Soleus, Plantaris, Extensor Digitorum
Longus of 6-week old male C57 BL/7 mice. Briefly, the
muscle groups were dissected out and treated with Col-
lagenase Type 1 (Cat# LS4196 Worthington 400U/ml fi-
nal concentration) for 1 h at 37◦C. Post collagenase treat-
ment individual muscle fibers were picked and fixed with
4% paraformaldehyde for 15 min at room temperature
(RT). For immunostaining, single fibers were washed with
1× PBS twice and mounted on charged slides (Cat#12-
550-15, Fisher Scientific). The fibers were permeabilized
with 0.5% Triton-X-100 in 1× PBS for 1h at RT followed
by blocking with 1× PBS, 0.5% Triton-X-100,10% nor-
mal goat serum for 1 h at RT. Primary antibody incuba-
tions were performed overnight at 4◦C with anti-RIZ1and2
(Cat # ab3790 Abcam) and anti-Pax7 antibody (DSHB).
Secondary antibody incubations were for 1 h at RT us-
ing fluorescently tagged antibodies from Invitrogen. Anti-
body incubations were followed by three washes with PBS
+ 0.05% Tween20. 4’,6-Diamidino-2-Phenylindole (DAPI)
(Cat# 32670 Sigma) was used to stain the DNA. Confocal
images were acquired using Zeiss LSM 510 Meta confocal
microscope.
Stable knockdown by RNAi
shRNAs complementary to the target PRDM2 or con-
trol GFP transcripts were cloned into mU6 vector. Stable
C2C12 myoblast pools expressing shRNAs were generated
by transfection and selection in G418. Aliquots of stable
transfectants were frozen back afterminimal expansion and
freshly revived cultures used for only one passage post thaw-
ing. Sequences are listed in Supplementary Information.
Several hairpins were tested but only one gave reproducible
knockdown of PRDM2 transcripts and protein.
RNA interference using siRNA
siRNA (Eurogentec) targeting a different sequence in
PRDM2 from the shRNA described above or scrambled
control siRNA (Ambion, proprietary sequence) were trans-
fected into C2C12 myoblasts. A total of 300 000 C2C12
cells were seeded in a P100 dish. Twenty-four hours later
400 pmol of siRNA was transfected using Lipofectamine
RNAiMax (using manufacturer’s protocol). The cells were
harvested in RIPA buffer 24 h later and analyzed by west-
ern blotting for PRDM2 knockdown and various histone
modification marks. Sequences are listed in Supplementary
Information.
Over-expression of flag-RIZ constructs
cDNAs for full-length mRIZ1 (1–5127 bp) or mRIZ2
lacking the PR domain (600–5127 bp) were amplified
from a mouse RIZ cDNA expression construct (Origene
MR227154) and cloned into pEF1-Fbek3. C2C12 my-
oblasts in GM were transiently transfected with the Flag-
tagged mRIZ1 or mRIZ2 using Lipofectamine and 12 h
later were either pulsed with BrdU for 30 min (to detect
proliferation) or were switched to FM for 36 h and then
processed for detection of Flag-RIZ proteins and BrdU or
myogenic markers.
Luciferase activity of promoter-reporter constructs was
assayed 24 h after transfection using a dual reporter kit
(Promega). Amounts of lysate representing equal protein
were used and normalized to transfection efficiency.
Immuno-fluorescence
Myoblasts stably expressing GFPsh or PRDMsh were
plated on coverslips, fixed with 3.5% formaldehyde and per-
meabilized in PBS, 0.2% Triton-X-100. Primary antibod-
ies were diluted in PBS, 0.2% Triton-X-100, 10% horse
serum. Secondary antibodies were goat anti-mouse-Alexa
fluor 488 or goat anti-rabbit-Alexa fluor 594. Antibody in-
formation is detailed in Supplementary Information. Stain-
ing was recorded on a Zeiss 510 Meta laser scanning confo-
cal microscope (63×, Plan Apochromat Zeiss objective, 1.4
N.A.; LSM5 software). Images were minimally adjusted for
brightness and contrast using Adobe Photoshop 6.0.
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Flow cytometric analysis of DNA content
GFPsh and PRDM2sh myoblasts were arrested in G0,
harvested, washed in PBS, fixed in ice-cold 80% ethanol,
washed and resuspended in PBS + 1%Triton-X-100, 50
g/ml propidium iodide (PI) and 100 g/ml DNAse free
RNase for 30 min at 37◦C. Analysis was performed on a
FACS Calibur (BD Bioscience) using doublet discrimina-
tion. Data were acquired using CelQuest R© and analyzed us-
ing FLOWJOR©.
Histone Methyl Transferase (H3K9) HMT assay
Flag-tagged mouse RIZ1, RIZ2 or G9a were overex-
pressed in C2C12 mouse myoblasts. Forty-eight hours post
transfection cells were lysed in RIPA buffer. RIZ1/2 and
G9a were immunoprecipitated from cleared lysates us-
ing Flag antibody (Sigma Cat#F1804) and Protein A/G
Plus agarose beads. The immunoprecipitated beads were
tested for Histone Methyltransferase (H3K9) activity us-
ing an EpiQuik Histone Methyltransferase Activity Assay
Kit (Epigentek, Cat#P-3003) as per manufacturer’s proto-
col. Protein in IP samples was quantitated by Amido black
staining and HMT Activity was calculated after normaliz-
ing to equal protein. G9a and the control enzyme from the
kit (0.3 g) were used as positive controls and empty vector
transfected into C2C12 cells was used as a negative control.
Interaction analysis of PRDM2 isoforms with EZH2
HEK293T cells were transfected with MSCVhygro-F-
EZH2 (Addgene), pEF1-BirA-V5 and pEF1-Fbek plas-
mids containing either no insert (empty vector control)
or mRIZ1 or mRIZ2. Forty-eight hours post transfection,
cells were lysed in modified RIPA buffer (50 mM Tris–HCl
pH 7.4, 150 mM NaCl, 1% NP40, 0.25% sodium deoxy-
cholate, 1 mM EDTA) containing protease inhibitor cock-
tail (Roche), 1mMPhenyl methyl sulfonyl fluoride (PMSF),
0.5 mM Dithiothreitol (DTT) for 30 min. Cleared lysates
(equal protein) from control and biotin-tagged RIZ trans-
fectants were subjected to streptavidin pull downs using
prewashed Dynabeads (M-280 Streptavidin, Cat#11205D,
Invitrogen), for 16 h at 4◦C. Post incubation, the beads
were washed thrice with PBS + 0.5% TX100, bound pro-
teins eluted in 2× Laemmli sample buffer, loaded onto
Sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis gel and subjected to western blotting. The primary an-
tibodies used were anti-biotin HRP (Cat#7075S, Cell Sig-
naling Technology) and anti-EZH2 (Cat#CS203195, Mil-
lipore). HRP-conjugated secondary antibodies used were
from Jackson ImmunoResearch. Blots were developed us-
ing ECL detection reagent (Amersham) and imaged using
ImageQuant (GE Amersham).
cDNA microarray analysis (growing myoblasts)
Total RNA was isolated from GFPsh and PRDM2sh my-
oblasts in growth conditions, fluorescently labeled cDNA
synthesized with Cy3 andCy5 and competitively hybridized
to NIA15K mouse cDNA arrays as described (5). Two
arrays were used for each sample pair including dye re-
versal and biological replicates. Slides were scanned us-
ing a Molecular Dynamics scanner (Image Quant soft-
ware). Data was normalized using a Lowess normalization
method (TIGR software) and significant genes (false dis-
covery rate <5%) and 1.6-fold cut off, were designated by
Significance Analysis of Microarrays (SAM, Stanford).
Affymetrix microarray analysis (Quiescent and Differenti-
ated cells)
Total RNA isolated from G0 arrested and 28 h differ-
entiated muscle cells (GFPsh or PRDM2sh) was con-
verted to cDNA using One-cycle labeling kit and ampli-
fied using IVT labeling kit following manufacturer’s in-
structions (Affymetrix). The normalized cRNA was frag-
mented, hybridized to mouse Affymtrix Gene-chips (430
2.0), washed, stained and scanned as per Affymetrix pro-
tocols. The experiment was repeated with three different
biological replicates and data analyzed using Affymetrix
Gene Chip operating software (GCOS). The data were nor-
malized using PLIER (Affymetrix 2005) algorithms from
Avadis and subjected to standard differential expression
analysis (MIAME-compliant data is available at GEO ac-
cession GSE58676). Genes showing >1.5-fold differential
expression with P ≤ 0.05 were selected and a subset vali-
dated by real time Q-RT-PCR.
QRT-PCR
Quantitative real time PCR analysis was performed on an
ABI 7900HT thermal cycler (Applied Biosystems). cDNA
was prepared from 1 g total RNA using superscript
II (Invitrogen) and used in SYBR-Green assay (Applied
Biosystems)-each sample was isolated from three indepen-
dent biological samples and analyzed in triplicate. Ampli-
cons were verified by dissociation curves and sequencing.
Primer sequences are listed in the Supplementary Informa-
tion. Relative abundance of different mRNAs in PRDM2sh
G0 myoblasts was calculated with reference to GFPsh G0
myoblasts and normalized to GAPDH levels. Fold change
was calculated using normalized cycle threshold value dif-
ferences 2−ct.
RNA isolated from human myoblasts was analyzed on
QuantStudio 12D Flex (Applied Biosystems), using qbase-
Plus (Biogazelle) with PGK1 and TBP as reference genes.
Chromatin Immunoprecipitation (ChIP)
Chromatin was isolated and Chromatin Immunoprecipita-
tion (ChIP) performed using antibodies against various his-
tonemodifications andH3 as described previously (11). The
polyclonal antibody against PRDM2 recognizes both iso-
forms (detailed antibody information is provided in Sup-
plementary Information). Sonication conditions were op-
timized for each cellular state separately as the nuclear
configuration differs (details are available on request). For
ChIP-qPCR analysis, chromatin derived from 106 wild-
typeC2C12myoblasts,GFPsh or PRDM2shmyoblasts was
processed using antibodies against PRDM2, H3K4me3,
H3K9me2/3,H3K9Ac3 andH3K27me3. Fold enrichments
were calculated as% enrichment of input chromatin or as
fold change over the IgG control. Each samplewas analyzed
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as three technical replicates and data reported are derived
from three independent biological experiments.
Re-ChIP analysis
Sequential ChIP was carried out as per manufacturer’s in-
structions using the Re-ChIP-IT kit from Active Motif
(Cat#533016). ChIP-1 used anti-H3K4me3 and the eluted
chromatin was first checked against known controls and
then subjected to ChIP-2 with anti-H3K27me3.
Chromatin-Immunoprecipitation coupled withDNAmicroar-
ray (ChIP–Chip)
ChIP–Chip analysis was performed using Agilent 244K
promoter arrays (Genotypic Technologies, Bangalore) rep-
resenting 22 170 murine promoters. The array design in-
cludes 60-mer probes (Mouse NCBI36/mm8 Assembly)
tiled at 200 bp resolution encompassing a 4 kb region sur-
rounding each TSS (−2.5 to +1.5 kb).
Chromatin immuno-precipitation was performed with
chromatin isolated from 3 × 106 quiescent myoblasts using
ChIP assay kit (Upstate, #17–295) according to the man-
ufacturer’s protocol. Briefly, cells were cross-linked using
1% formaldehyde (Fisher Scientific) in GM for 10 min and
quenched with 0.125 M glycine (Sigma). Fixed cells were
washed well with 1× PBS containing protease inhibitors
at 4◦C and resuspended in 2 ml lysis buffer supplemented
with PMSF, DTT and protease inhibitor cocktail (Roche).
Following 15 min incubation on ice, the sample was son-
icated using Bioruptor (Diagnode) to obtain fragments of
average size 200–600 bp. ChIP assays were performed using
5 g of polyclonal antibody against PRDM2 (recognizes
both isoforms) or H3K9me2 (Abcam, #ab1220). Following
crosslink reversal and amplification by ligation-mediated
PCR, the enriched and input fractions were labeled with
Cy5 and Cy3 dyes respectively (Agilent DNA labeling kit,
#5190–0449) and subjected to dual color hybridization at
65◦C for 40 h to the promoter arrays. The arrays were
washed and scanned and data was extracted using Agilent’s
feature extraction software.
ChIP–chip data analysis
Normalized enrichment values were determined using
DNAAnalytics 4.0 (Agilent). Peaks were determined by an-
alyzing the distribution of all the probes in the array to as-
sign p-values to each event andmake binding calls using the
Whitehead Per-Array NeighborhoodModel, which consid-
ers the P-value of each probe in conjunction with both its
immediate neighbors. A binding event was called if the com-
posite P-value of groups of three probes was less than a set
cutoff of 0.05; only peaks called in both the duplicates were
retained for analysis. In the experiments reported here, the
Pearson correlation coefficient of duplicate ChIP–chip ar-
rays was 0.617.
For calculation of total bound promoters, probe IDswere
used. For all comparisons across platforms and Gene On-
tology (GO) analysis, unique Unigene IDs were used.
Validation of ChIP–chip data
A subset of 10 promoter regions were validated by real time
ChIP-qPCR using sequences called as positively enriched
(13 probes) or negatively enriched (10 probes) from the
ChIP–chip array. Primer sequences for validation of ChIP–
chip data with details of amplicon size are listed in Sup-
plementary Information. Fold enrichments were calculated
with respect to input normalized to the IgG control.
Statistical analysis
Other than ChIP–chip, (which represents duplicate arrays),
all data represents values derived from at least three biologi-
cal replicates and is represented as mean± S.E.M, analysed
using Student’s two-tailed t-test, where P < 0.05 was taken
as significant.
RESULTS
Quiescent cells must execute a balancing act: both prolif-
eration and differentiation are held in abeyance, but must
be available for activation during regeneration. The mech-
anism by which this balance is maintained in G0 is not
known, but likely involves chromatin regulation. To test this
hypothesis, we analyzed the function of epigenetic modula-
tors that are specifically induced in G0.
PRDM2/RIZ is expressed by quiescent cells invitro and in-
vivo
We identified PR domain containing-2/Rb-interacting zinc
finger protein (PRDM2/RIZ) as a gene whose expression
was upregulated in G0 (10). Twomajor mRNAs are known-
RIZ1 (7.3 kb) has an N terminal PR domain (modified
SET/HMT motif) and RIZ2 (7 kb) lacks the PR domain
(35) (Supplementary Figure S1). RIZ1-specific as well as
total PRDM2/RIZ mRNA was induced in G0 synchro-
nized C2C12 myoblasts (MB), and waned as cells re-enter S
phase (Figure 1A left panel). During differentiation to MT,
PRDM2 expression was repressed (Figure 1A, right panel).
Expression of PRDM2marked Pax7+ satellite cells (SC) on
isolated mouse myofibers (Figure 1B) and purified quies-
cent mouse SC (Figure 1C), declining during activation or
differentiation in vitro (Figure 1D). PRDM2 was detected
in presumptive SC in human fetal and adult muscle (Figure
1E and F) and was induced as human primary SC-derived
myoblasts, bone marrow-derived MSC and primary fibrob-
lasts entered G0 in culture (Figure 1G–I). Thus, PRDM2 is
enriched in reversibly rather than irreversibly arrested cells,
suggesting G0-specific functions.
Knockdown of PRDM2 does not hasten the cell cycle, over-
expression causes arrest
To analyze the role of PRDM2 in G0 myoblasts, we used
shRNAs that target both isoforms and confirmed reduced
expression at bothmRNAand protein level (Figure 2 A and
B). As a known tumor suppressor, loss of PRDM2 might
enhance proliferation, as in MCF7 cells (36). However, in
MB, knockdown of PRDM2 reduced proliferation as evi-
denced by reduced cyclin expression (Figure 2C) and fewer
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Figure 1. PRDM2 is highly expressed in quiescent cells. (A) PRDM2/RIZ mRNAs are upregulated in C2C12 MBs in G0 and wane during S phase entry
(left panel); both transcripts are downregulated during differentiation (right panel). Q-RT-PCR analysis with primers specific to RIZ1 (blue bars); primers
to detect both RIZ1 + RIZ2 mRNAs (pink bars); MB: asynchronous cycling MB; G0: quiescent, R2-R24: 2–24 h after reactivation from G0; D12-D96:
12–96 h of differentiation. (B) PRDM2 protein is expressed by Pax7+mouse SCs (arrow) on isolatedmyofibers; myonuclei (arrowhead) do not express Pax7
or PRDM2. Note: antibody detects both PRDM2 isoforms (RIZ1/2). (C) PRDM2 expressed by freshly sorted quiescent mouse SC. Top- Phase contrast;
Middle- SC markers Desmin and Pax7 (Bar 20 ); Bottom-PRDM2 is also expressed (Bar 10 ). (D) Q-RT-PCR analysis of primary SCs: freshly isolated
quiescent (QSC, red), activated for 24 h in GM (ASC, blue) or differentiated for 24 h in DM (DM, green). QSC show low Cyc E expression but induction of
G0 markers p27, Rgs2, and up-regulation of PRDM2 mRNAs. (E) PRDM2 expression in presumptive SCs (arrowheads) in fetal human muscle sections.
(F) PRDM2 in adult human muscle section (arrowhead)––inset shows magnified PRDM2+ SC (brown). (G) Upregulation of PRDM2mRNAs in cultured
G0-synchronized primary human SC. (H) PRDM2 mRNA up-regulation in cultured G0-synchronized primary hMSC. (I) PRDM2 mRNA is induced in
serum-starved quiescent human primary fibroblasts, and suppressed by cell cycle reactivation. Values in all graphs represent the mean ± S.E.M., n = 3.
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Figure 2. PRDM2 is not a typical quiescence factor: knockdown further slows the cell cycle. Stable knockdown of PRDM2 mRNA and protein in C2C12
myoblasts using shRNA targeting both RIZ1 and RIZ2 mRNAs (control is GFP shRNA). (A) Q-RT-PCR analysis of RNAi in growing and G0 MBs-
reducedmRNA. (B) Reduced levels of RIZ1 andRIZ2 proteins (antibody recognizes both isoforms). PRDM2knockdown cells show reduced proliferation:
(C) Reduced CycD1, CycA2 mRNA levels, (D and E) reduced BrdU incorporation and (F) reduced colony formation. (G) Over-expression of Flag-tagged
mRIZ1 detected with anti-Flag (purple) or anti-PRDM2 (red). (H) Flag-tagged mRIZ1 and mRIZ2 are expressed at similar levels. (I) H3K9 methyl
transferase assay of Flag-tagged mouse RIZ1, RIZ2 and G9a in myoblasts. mRIZ1 shows HMT activity equivalent to mG9a, whereas mRIZ2 does not
(Con, empty Flag vector; Enz, purified HMT enzyme (0.3 g) as positive control; values represent mean + SEM, n = 3 for RIZ1/2, n = 2 for G9a). (J
and K) Both RIZ1 and RIZ2 when ectopically expressed suppress BrdU incorporation (values represent mean ± SEM; P < 0.01 for mRIZ1, P < 0.001
for mRIZ2, n = 3) and myogenic markers (P < 0.001, n = 3) compared to control (Con, empty Flag vector).
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S phase cells (Figure 2D, E), and also reduced self-renewal
as seen by lower colony formation (Figure 2F).
The PR/SET domain defines the PRDM family of hi-
stone modifiers (37). Of the PRDM2 isoforms, RIZ1 (an
H3K9 methyl transferase, (38,39) is deleted in cancers, but
RIZ2, which lacks the PR domain, is not; targeted deletion
of just RIZ1 increased tumor incidence (40). When exoge-
nously expressed in myoblasts both isoforms were nuclear
localized (Figure 2G) and expressed to similar levels (Figure
2H). To assess the enzymatic activity of the two isoforms, we
performed histone methyl transferase assays on flag-tagged
mRIZ1 and mRIZ2 proteins after immuno-precipitation.
WhilemRIZ1was capable ofmethylatingH3K9 to a similar
extent as a proven H3K9 transferase G9a, mRIZ2 did not
show detectable activity (Figure 2I). When over-expressed
in cycling MB (Figure 2J and K), both mRIZ1-flag and
mRIZ2-flag inhibited proliferation (Figure 2J), consistent
with the reports that PRDM2/RIZ is a negative regulator
of the cell cycle (41). Interestingly, both isoforms also re-
pressed markers of commitment, differentiation and irre-
versible arrest (MyoD, MyoG, p21) (Figure 2K). Taken to-
gether with the down-regulation of this tumor suppressor
during differentiation (Figure 1) these findings suggest that
induction of PRDM2/RIZ in G0 may prevent inappropri-
ate differentiation and promote reversible arrest.
PRDM2/RIZ knockdown accelerates differentiation
To assess the effects of PRDM2 RNAi on differentiation,
we used siRNA and shRNA to target different sequences
and examined expression of myogenic markers both in GM
and in differentiation medium (DM). Knockdown cells dif-
ferentiated precociously in GM (Figure 3A and B) and
showed MT hypertrophy in DM (Figure 3C), confirming
PRDM2 as a repressor of myogenesis. In G0 conditions,
controlMB remained mono-nucleated, but PRDM2sh cells
fused to form syncytia (Figure 3D). Thus in muscle cells,
PRDM2 maintains an undifferentiated state.
We directly examined a role for PRDM2 in regulating
muscle genes. MyoG is a target of several chromatin mod-
ulators (22), including the H3K9 methyltransferase Suv39h
(42). Using ChIP, we found that PRDM2 associates with
the MyoG promoter in undifferentiated MBs (Figure 3E):
this association is enhanced in G0 but lost in MTs, con-
sistent with a differentiation-blocking role. We located a
consensus PRDM2 binding site (GTTGGC) overlapping
a MEF2c site in the critical −200 bp region of the MyoG
promoter, suggesting direct binding (43), (Supplementary
Figure S2). In PRDM2sh cells cultured in either GM or
DM, an ectopic MyoG promoter-luciferase construct was
de-repressed (Figure 3F). Since PRDM2 exhibits H3K9
methyl transferase activity (38) (this report Figure 2), we as-
sessed histone modifications at the endogenous MyoG pro-
moter in G0 cells, using ChIP assays. Knockdown cells not
only showed reduced H3K9me2, consistent with reduced
PRDM2 association, but also increased H3K14Ac (a mod-
ification that promotes gene activation) (Figure 3G), corre-
lating with the de-repression of promoter activity (Figure
3F). Overall levels of H3K9-me1/2/3 were unchanged in
the PRDM2 knockdown cells (Supplementary Figure S3),
suggesting only locus-specific alternations. Together, these
results demonstrate that PRDM2 directly targets an early
differentiation control hub via repressive histone marks,
specifically in G0.
PRDM2 functions peak in G0, knockdown grossly alters qui-
escence program
To examine the extent and timing of PRDM2’s influence, we
used stage-specific microarray analysis (Figure 3H and I).
In cycling and differentiating conditions, reduced PRDM2
expression had minor effects: only 36 and 26 genes respec-
tively showed altered expression (Supplementary Tables S1
and S2). However, in G0 conditions, PRDM2 knockdown
MB showed altered expression of 1420 genes (Supplemen-
tary Table S3; data can be retrieved from GEO accession
GSE58676). This 50-fold greater effect on the transcriptome
suggests that the critical period of PRDM2 function is G0.
GO analysis corroborated the phenotypic analysis of the
knockdown (Figures 2C–F and 3A–D) revealing that the
most highly enriched terms included muscle developmental
genes, signaling and the cell cycle (Figure 3I). Of 543 down-
regulated genes, >50% participate in proliferation (Supple-
mentary Figure S4A), pointing to amajor effect of PRDM2
on the cell cycle. About 10% of 877 upregulated genes are
involved in differentiation and 2.5% in muscle contraction,
consistent with PRDM2’s repressive role. GO analysis us-
ing a different algorithm that reduces redundancy in large
datasets (http://revigo.irb.hr/revigo.jsp) (44) highlighted the
enrichment of the muscle regulatory program in the upreg-
ulated genes and cell cycle program in the downregulated
genes (Supplementary Figure S4B). Thus, PRDM2 func-
tions peak in G0 and knockdown subverts the quiescence
program.
Validation of 12 microarray hits by Q-RT-PCR con-
firmed that loss of PRDM2 promotes myogenesis: MyoG,
p21 and Mef2c were strongly induced (Figure 3J, left), as
were upstream regulators (IGF2), and downstream targets
(myosins, troponins) that build sarcomeres (Supplementary
Table S3). Thus, PRDM2 represses the muscle hierarchy
at multiple levels. With both cell cycle and myogenesis re-
pressed inG0, this quiescent, undifferentiated state is poised
for activation of either program. The role of PRDM2 in
promoting the G0 state was evident: induction of differ-
entiation in knockdown cells was coupled with hallmarks
of irreversible arrest: Cyclins D1, E, A2, B that are nor-
mally repressed in G0 were hyper-repressed (Figure 3J,
middle); developmental/cell fate regulators (Pax7, Myf5,
CD34, Jmjd1a) that are normally maintained or induced
in G0 were repressed (Figure 3J, right). Together, these re-
sults demonstrate that PRDM2 preserves reversibility of
quiescence, not only by fail-safe repression of differentia-
tion genes, but also by maintaining expression of stem cell
and cell cycle genes.
PRDM2 orchestrates a global program by association with
4480 promoters
To investigate potential direct targets of PRDM2, we de-
termined its genome-wide location in G0 MB using ChIP–
Chip analysis of Agilent 244K mouse promoter arrays.
Duplicate arrays were interrogated with chromatin derived
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Figure 3. PRDM2 is a master repressor of muscle differentiation in G0: knockdown diverts quiescence program to differentiation. PRDM2 knockdown
by siRNA (A) or shRNA (B) leads to precocious induction of early muscle markers, MyoG, p21 and CycD3. (C) Increased MyoG+ nuclei in GM (MB),
precocious fusion and larger myosin+ MT after 48 h in DM (D48). (D) Fusion in knockdown cells even in G0-inducing conditions: membrane marker
PKH26 (red) reveals multinucleated syncytia (right panel); control cells remain mononucleated (left panel). (E) ChIP analysis shows PRDM2 association
with MyoG promoter in MB; this is enhanced in G0 and lost in MT. (F) PRDM2 knockdown de-represses MyoG promoter activity-transfection of a
MyoG promoter-luciferase construct into control (GFPsh) or knockdown (PRDMsh) cells in proliferating (MB), 12 or 24 h differentiating conditions
(D12, D24). (G) Altered histone marks on MyoG promoter [−120 ± 10 bp] in knockdown (reduced H3K9me2, increased H3K14acetyl) correlate with
increased transcriptional activity in PRDM2sh cells in G0-inducing conditions [normalized mean% enrichment ± S.E.M, n = 3; *P < 0.05; **P < 0.005].
(H) Affymetrix gene-arrays reveal only ∼26 genes differentially expressed (≥1.5-fold) between GFPsh and PRDMsh cells when cultured in DM for 28
h (top panel, Supplementary Table S2), but >1400 genes in G0-inducing conditions (bottom panel, top 100 up- and downregulated genes are listed in
Supplementary Table S3). (I) Pathway analysis of deregulated transcripts using DAVID (http://david.abcc.ncifcrf.gov/): values represent enrichment scores.
Note the substantial representation of GO terms representing muscle specification, development and proliferation. (J) Targeted Q-RT-PCR validation of
12 key transcripts deregulated by PRDM2 knockdown in G0. Myogenic regulators are upregulated (left panel), but regulators of cell cycle (middle panel)
and cell fate (right panel) are downregulated, confirming that PRDM2 normally restrains differentiation genes but maintains proliferation and specification
genes.
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from independent pull-downs using a polyclonal PRDM2
antibody that recognizes both isoforms RIZ1 and RIZ2,
and compared with a third array probed for H3K9me2
marks. Figure 4A depicts the binding intensity traces for the
entire chromosome 3, showing the high degree of correla-
tion between replicates; Figure 4B shows the CCNA2 locus
indicating PRDM2 enrichment specifically at the TSS and
in intron 1. The genome-wide analysis revealed that 4480
gene promoters were occupied by PRDM2 in quiescence
(P < 0.05), of which 2462 (55%), were co-associated with
H3K9me2 marks (Figure 4C). ChIP–chip data is available
at GEO accession number GSE58748. In conjuction with
the confirmed enzymatic activity of RIZ1, the observation
that over half of PRDM2 binding sites in chromatin also
show H3K9me2 enrichment, may suggest a role for this tu-
mor suppressor protein in wide-spread chromatinmodifica-
tion. Since the antibody does not distinguish isoforms but
only RIZ1 is capable of H3K9methylation, concievably, the
RIZ1 isoform may co-localize with H3K9me2 at common
chromatin sites, and sites not enriched for H3K9me2 may
represent sites of RIZ2 binding.
Pathway analysis of PRDM2-bound promoters us-
ing DAVID underscored the broad regulatory function
of this epigenetic regulator, showing enrichment of GO
terms for control of transcriptional, developmental, dif-
ferentiation, signaling, oncogenic and cell cycle pro-
grams (Figure 4D). Interestingly, the list of PRDM2-
associated promoters contained a strong signature of neu-
rogenic and neuro-modulatory genes, suggesting functions
in developmental/differentiation programs beyond muscle.
GO analysis to evaluate non-redundant terms highlighted
the enrichment of myogenic, cell cycle and stem cell pro-
grams (Supplementary Figure S5).
Sequence analysis of the bound promoters revealed
that 860 probe sets showed a consensus PRDM2 bind-
ing site (C/GTTGGC (Figure 4E), suggesting direct bind-
ing: 560 of these were co-associated with H3K9me2 in
G0. Bio-informatic analysis also suggested indirect bind-
ing of PRDM2 at some locations: 208 promoters that
were seven to nine-fold enriched by PRDM2 ChIP, [E-
value 1.6e−11] (Figure 4F), 70% of which were also en-
riched for H3K9me2, harbored CpG islands but not canon-
ical PRDM2 binding sites. This finding suggests potential
recruitment of PRDM2 by mechanisms other than direct
DNA binding and possible cooperation between DNA and
histone methylation at these loci.
Targeted ChIP-QPCR analysis (Figure 4G, left panel) of
10 selected promoters showing PRDMoccupancy was used
to validate the ChIP–Chip analysis (Figure 4G right panel).
In these 10 promoters, all 13 regions called as positively en-
riched and all 10 negatively enriched regions reproducibly
yieldedChIP-qPCR enrichment values in concordancewith
the ChIP–chip analysis. We confirmed that PRDM2was lo-
cated not only at MyoG promoter in G0 (Figure 3E), but
also at promoters of upstream myogenic regulators (IGF2,
Meis1), and at promoters of cyclin and stem cell regulatory
genes (Figure 4G).
To determine potential direct transcriptional targets
of PRDM2, we compared the transcriptome analysis
with the chromatin occupancy analysis of both PRDM2
and H3K9me (Figure 4H and I). Of 1420 genes whose
expression was altered in PRDM2 knockdown cells,
the promoters of 22.1% were enriched for PRDM2,
19.5% showed H3K9me2 enrichment and 11.5% were
co-occupied, in concordance with reports that no single
epigenetic/transcriptional regulator is critically required at
all its binding sites (45,46). Of the 314 PRDM2-occupied
loci that were de-regulated in the PRDM2 knockdown
myoblasts, 163 loci were also associated with H3K9me2
(109 were upregulated ≥1.5-fold in PRDM2sh and 54 were
downregulated) (Figure 4H, Supplementary Table S4). The
observation that most dually enriched promoters are not
deregulated is likely a consequence of redundant regulatory
mechanisms (45). However, pathway analysis confirmed
that developmental, muscle, cell cycle and signaling path-
way genes were enriched in the gene sets that were both
bound by PRDM2 and deregulated in the knockdown (Fig-
ure 4I). Taken together, genome-wide location and expres-
sion analysis in G0 suggest that by interacting with pro-
moters that control antagonistic functions (differentiation
versus stemness, proliferation versus quiescence), PRDM2
may orchestrate a complex program that maintains cells
poised for alternate fates.
PRDM2 maintains expression of stem cell genes in G0
PRDM2 participates in both repressive and activating com-
plexes in MCF7 cells (47). In G0 MBs, PRDM2 not only
associates with muscle promoters (MyoG, IGF2) whose ex-
pression is enhanced in knockdown cells (Figures 3 and 4),
but also with those of pluripotency genes (Oct4, Jmjd1a)
and tissue-restricted fate regulators (Pax7, CD34) (Figure
4), whose expression declines. As an H3K9 methyl trans-
ferase, PRDM2’s regulation of Jmjd1a (an H3K9 demethy-
lase) suggests a feed-back mechanism that may potentiate
differentiation in PRDM2sh cells. Loss of SC markers in
RNAi cells also suggests that PRDM2 may normally asso-
ciate with an activating/maintenance complex at these loci;
by contrast, at the activated muscle marker genes, PRDM2
may normally participate in a repressive complex.
PRDM2/RIZ prevents silencing of cell cycle genes in re-
versible arrest
During differentiation, silencing of cell cycle activators by
the H3K9 transferase Suv39h reinforces permanent exit
(25). However, transient quiescence requires reversible re-
pression of cell cycle genes, necessitating mechanisms to
keep them off but poised for re-activation by mitogenic
cues. Knockdown of PRDM2 led to hyper-repression of
cyclins (Figure 3), suggesting that this chromatin factor
may maintain basal activity of these promoters in G0
and/or preserve their competence for future induction. To
test this hypothesis, we analyzed the Cyclin A2 (CCNA2)
promoter (Cell Cycle Regulatory Element) for repressive
(H3K9me2) versus silencing (H3K27me3) marks. We also
assessed H3K4me3, since this normally activating mark
correlates with CCNA2 repression in G0 (11) and CCNA2
was 50-fold downregulated in PRDM2 knockdown cells
(Figure 3J). In control cells (GFPsh) in G0, CCNA2 CCRE
was more enriched for H3K4me3 and H3K9me2 than for
H3K27me3 (Figure 5A). However, PRDM2sh cells showed
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Figure 4. Genome-wide promoter analysis in G0 myoblasts reveals PRDM2 association with a broad program including regulators of the cell cycle,
differentiation and stem cell functions. ChIP–Chip analysis (Agilent 244K mouse promoter arrays) using total PRDM2 antibody reveals that PRDM2
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a switch in modifications: H3K27me3 was strongly en-
riched, coinciding with reduced H3K9me2 and H3K4me3.
Thus, PRDM2may block the deposition of silencing marks
on cell cycle genes in G0, preserving their potential for fu-
ture reactivation.
A quiescence-dependent bivalent domain in the CCNA2 gene
To assess whether PRDM2 regulates silencing-associated
marks specifically in G0, we first profiled histone modifi-
cations on the CCNA2 gene (region from −600 bp to +2
kb) in different states (Figure 5B). Of the activating marks,
H3K9Ac is enriched around the TSS (−100 bp to +1 kb re-
gion) only in MB where the gene is expressed, but not in
either G0 orMT; H3K4me3 is enriched in both G0 andMB
but not in MT, as reported (11). The repressive H3K27me3
mark is enriched in both states where CCNA2 is not ex-
pressed (G0, MT), but not in MB. Integrating H3K4me3
and H3K27me3 marks across the CCNA2 gene in three
states, a ‘bivalent domain’ enriched for both activating and
repressive marks was found between +200 bp to +1 kb,
specifically in G0 (Figure 5C). In MB and MT, this do-
main resolves to singly marked status in accordance with
CCNA2 expression status: in proliferating MB, the activat-
ing H3K4me3 mark is retained, while differentiatedMT re-
tain the repressive K27me3 mark (Figure 5C, top). Bivalent
marking was not observed at MyoG promoter/TSS in any
state (Figure 5C, bottom), indicating specificity for CCNA2
promoter inG0. To eliminate the possibility that dual mark-
ing reflects population heterogeneity, bivalency was further
confirmed by sequential ChIP (‘re-ChIP’) analysis (Figure
5D).
To map the kinetics of histone modifications at the bona
fideCCNA2bivalent domain, we usedChIP analysis of syn-
chronized cell cycle re-entry from G0 revealing that biva-
lency resolves at G1/S (Supplementary Figure S6A) when
CCNA2 expression rises (Supplementary Figure S6B), after
which only H3K4me3 is retained. This dynamic chromatin
regulation of CCNA2 is distinct from transcriptional con-
trol of the S-phase specific CCRE (48) revealing epigenetic
control of a key regulator of DNA replication, specifically
in G0.
To determine whether other cell cycle promoters are also
bivalently marked, we examined the CCND1 promoter and
TSS during proliferation, quiescence and differentiation.
We observed that while H3K4marks were strongly retained
in G0 although the locus is transcriptionally repressed, nei-
ther promoter nor TSS showed equivalently strong H3K27
marking to the extent seen forCCNA2 (SupplementaryFig-
ure S7). Thus, the individual cyclin loci may experience dis-
tinct epigenetic regulation in G0 and the bivalent domain in
CCNA2 may represent a specific cell cycle regulatory node.
A novel Polycomb response element (PRE) in CCNA2 intron
1 binds PRC2 members and represses reporter gene activity
Cyc A is implicated as a direct target for Polycomb pro-
teins in flies (49,50), but such regulation has not been
documented in mammals. Given the intronic enrichment
of H3K27me3 (Figure 5), we analyzed the entire mouse
CCNA2 locus for PRE-like sequences. InDrosophila, PREs
associate with factors PHO, GAF and DSP1 (51), whose
vertebrate homologs, HMGB2, YY1, ThPOK respectively
(52–54) are known. We found two regions containing
YY1/GAF consensus sites along with a Drosophila PHO
consensus motif (55), in CCNA2 introns 1 and 2 (Regions 1
and 2 respectively) (Figure 6A). When cloned upstream of
luciferase reporter, both Regions 1 and 2 showed significant
repressive activity, equivalent to a known repressor element
in the EVX2–HoxD13 region (56) (Figure 6B), suggesting a
potential role as PREs. ChIP analysis determined that core
PRC2 member Suz12 was enriched at Region 1 and not Re-
gion 2 in G0 (Figure 6C). Thus, an intronic element in the
mouse CCNA2 gene contains a PRE-like sequence that can
recruit PRC2members, and repress gene activity in reporter
assays.
Balanced occupancy of the CCNA2 PRE by EZH1 and
EZH2 is specific to G0
Since Suz12 was associated with the CCNA2 PRE in G0,
we determined the expression of PRC members in differ-
ent states. PRC2 members EZH1, EZH2, SUZ12 and EED
were all induced in G0 compared to MB and MT (Supple-
mentary Figure S8) and interestingly, PRDM2 was also as-
sociated with their promoters. PRC1 members (CBX fam-
ily) were also induced in G0. Thus, quiescence is uniquely
associated with increased expression of PRC1/2 members.
Correlating with dynamic changes in epigenetic marks at
CCNA2 locus, occupancy of the putative PRE by PRC2
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
proteins associate specifically with thousands of sites in the mouse genome. (A) The three tracks in the schematic depict the entire mouse chr.1 showing
the location of binding enrichment (vertical bars) of PRDM2 (RIZ REP1 and 2) and H3K9me2 from replicate ChIP–chip analysis. Y-axis represents
enrichment score (over input). (B) A zoomed view of the CCNA2 locus on chr.3; arrows depict the direction of transcription. Enrichment near TSS and
in intron 1 is evident. (C) A total of 4480 promoters (complete list available from GEO [GSE58676]) were bound by PRDM2 in quiescent MB (P < 0.05);
2462 promoters (55%) are also enriched for H3K9me2. (D) Annotation of PRDM2 bound genes using DAVID reveals a broad set of development- and
proliferation-related pathways (values represent enrichment scores). (E) Enrichment of known consensus PRDM2 binding site CTTGGC in 860 probes
suggests direct binding at these sites. (F) CpG motif is specifically enriched in probes that are most strongly associated with PRDM2 (seven to nine-fold
enriched). (G) Validation of global ChIP–chip analysis using targeted ChIP-qPCR of loci encoding positive regulators of myogenic differentiation (middle),
cell cycle regulators (top) and stem cell regulators (lower) in G0 MB. Primer coordinates were chosen based on enrichment in genome-wide analysis (see
Supplementary Information for details). For each locus, N = negatively enriched region, P = positively enriched promoter region, G = positively enriched
gene body region. Left panel: ChIP-qPCR validation [mean ± S.E.M (n = 3), ** P < 0.005, *P < 0.05 compared to respective IgG controls]; Right panel:
values derived from ChIP–chip analysis (P < 0.05). (H) Comparison of ChIP–chip analysis with transcriptome analysis reveals potential direct targets.
Overlap of genomic locations of PRDM2 association with genes deregulated by PRDM2 knockdown: 314 PRDM2 bound genes show altered regulation
suggesting these are direct targets of PRDM2. (I) Pathway analysis of PRDM2-associated and deregulated genes using DAVID enriches developmental
and cell cycle genes (values represent enrichment scores). Upper panel (blue bars) represents upregulated and lower panel (brown bars) represents down
regulated gene classes.
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Figure 5. PRDM2 regulates histone modifications at the CCNA2 locus: Identification of a quiescent-specific bivalent domain in intron 1 of the mouse
CyclinA2 gene. (A) PRDM2 prevents deposition of silencing marks on CCNA2 promoter. ChIP-qPCR analysis of histone modifications at the cell cycle
regulated element of the CCNA2 promoter (CCRE, +9 to +175) in control and PRDM2 knockdown MBs. In G0 conditions, reduced PRDM2 leads to
increased levels of silencing marks (H3K27me3) and loss of activation marks (H3K4me3), coincident with reduced H3K9me2, **P < 0.005. (B) Histone
modification profile of the−600 to +2000 region of CCNA2 gene in different cellular states byChIP-qPCR.Activatingmarks (H3K9Ac [purple], H3K4me3
[green]) dominate in MB (middle panel) and silencing marks (H3K27me3) dominate in MT (bottom panel). Uniquely, in G0 (top panel) CCNA2 exhibits
little H3K9Ac, but both H3K4me3 and H3K27me3, suggesting a balanced repressed state. The region between +200 and +600 is subject to greater
alterations in histone marks than at the known CCRE (mean ±SEM, n = 3; *P < 0.0001). (C) The CCNA2 intron 1 (+200 to +600) is bivalently marked
(H3K4me3 + H3K27me3) specifically in G0 (top panel), but singly marked in MB (H3K4) and MT (H3K27) in keeping with the active and silenced
transcriptional state of CCNA2 locus respectively. The MyoG promoter is not dually marked in any state (bottom panel)-silencing marks increase in G0.
(D) Validation of the G0-specific bivalent domain by sequential or re-ChIP analysis. Chromatin pulled down with anti-H3K4me3 was re-precipitated with
anti-H3K27me3 (left) or anti-K27 followed by anti-K4 (right) to assess whether the two marks are present on the same set of chromatin fragments or
two distinct sets. The Y-axis represents fold enrichment of H3K27me3 from an initial H3K4me3 pulldown. CCNA2 (+200 to +600 region) but not MyoG
promoter shows dual marking, and only in G0 cells not MB.
Nucleic Acids Research, 2015, Vol. 43, No. 13 6249
Figure 6. APRE-like element in the CCNA2bivalent domain shows cell state-specific EZH1 andEZH2 binding that is regulated by PRDM2. (A) Schematic
of CCNA2 locus: exons-red arrows; introns-thin red lines. YY1 binding sites (GCCATHWY), PHObinding sites (CNGCCATNDNND) andGAFbinding
sites (GGGAAGG, GAGGGG, GAGAG) are clustered in two distinct regions in introns 1 and 2 (Region 1 and 2) respectively). (B) Cloned Regions 1
and 2 repress luciferase reporter activity in transient transfection assays, compared to empty vector control. Positive control for repressor activity is a
known repressive element from EVX2–HoxD13 region; negative control is GAPDH gene (500 bp). Values represent normalized reporter activity (mean ±
S.D., n = 3; *P < 0.002). (C) SUZ12 (core member of PRC2 complex) is associated only with CCNA2 Region 1 and not Region 2 (SUZ12 occupancy at
MyoG TSS serves as a positive control) (mean ± S.E.M, n = 3). (D) The putative PRE in Region 1 shows balanced occupancy of EZH1 and EZH2 in G0,
but EZH1 occupancy dominates in MB, EZH2 dominates in MT (mean ± S.E.M, n = 3). (E) PRDM2 binds the CCNA2 gene only at the putative PRE
(+200 to +600), not at the CCRE. CCNE P and CCNE N are positive and negative controls respectively for PRDM2 binding (derived from ChIP–chip
and validated by ChIP-qPCR) from CCNE locus. (F) Knockdown of PRDM2 alters PRC2 complexes at the CCNA2 PRE in G0: reduced EZH1 and
increased EZH2 enrichment; Suz12 enrichment is unaltered. (G) Knockdown of PRDM2 leads to reduced H3K4me3 and increased H3K27me3 marks
at the CCNA2 PRE in G0, correlating with increased EZH2 occupancy (mean ± S.E.M., n = 3). (H) Expression of EZH2, like PRDM2 (see Figure 1) is
enriched in quiescent mouse SCs. Q-RT-PCR analysis of EZH1 and EZH2 in freshly sorted cells held in quiescent (QSC), activated (ASC) or differentiated
(DM) conditions. (I) PRDM2 interacts with EZH2. Biotin-tagged PRDM2 isoforms (mRIZ1 or mRIZ2) or the empty vector (Con) were transfected into
HEK cells, pulled down with streptavidin beads and probed for the presence of RIZ, EZH2 or GAPDH (negative control) using immuno-blotting. Input
samples contained several isoforms of EZH2, but only the 85 kD full-length EZH2 protein was specifically detected in RIZ1/2 pull downs. Data depicted
is one of three biological replicates.
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members also varied. EZH1 and EZH2 are H3K27 methyl
transferases that co-regulate ASC function (57). While
EZH1 was enriched in MB and EZH2 was enriched in MT,
G0 MBs showed balanced enrichment of both EZH1 and
EZH2 (Figure 6D). EZH1 is known to associate with active
loci (58,59).Hence, association of EZH1on a silent CCNA2
gene in G0 suggests a mechanism for poising the locus for
activation.
PRDM2maintains the EZH1-EZH2 balance at the CCNA2
PRE in G0
The original ChIP–chip analysis indicated that PRDM2 as-
sociates with the CCNA2 intron (Figure 4B). Using a gene-
specific ChIP assay, we found that PRDM2 is specifically
associated with the CCNA2 PRE-like element, but not with
the well-studied CCRE (Figure 6E). Importantly, PRDM2
knockdown affected association of EZH1 and EZH2 at the
intronic PRE, altering the balance by decreasing EZH1 and
increasing EZH2 (Figure 6F). In addition, PRDM2 knock-
down also altered the poised or bivalent marking, with re-
duced H3K4 and increased H3K27. Finally, EZH2 is more
highly expressed in quiescent satellite cells (Figure 6H). As
EZH2 is the major H3K27 methyl transferase of PRC2
complex, increased chromatin association combined with
increased H3K27me3 levels at the PRE and increased re-
pression of CCNA2 in PRDM2sh indicates a functional
interplay between EZH2 and PRDM2 in G0. Specifically,
PRDM2 appears to blunt the accumulation of EZH2 at the
PRE-like element in CCNA2.
PRDM2 knockdown disrupts the bivalent status of CCNA2
PRE
PRDM2 clearly helps to preserve CCNA2 expression in
quiescence since CycA2 mRNA levels were repressed ∼50-
fold more when PRDM2 expression was depleted (Figure
3). To determine if PRDM2 contributes to G0-dependent
histone marks, we examined H3K4me3 and H3K27me3
at CCNA2 PRE-like element: PRDM2sh cells showed re-
duced H3K4me3 and increased H3K27me3 levels (Figure
6G) suggesting that PRDM2 normally contributes to main-
taining the bivalent status of the PRE in G0. Enhanced
H3K27me3 levels in PRDM2sh correlate with, and likely
result in, hyper-repression of CCNA2 expression. Taken to-
gether, increased H3K27 marking and increased EZH2 as-
sociation at the PRE in PRDM2 knockdown cells, strongly
implicate PRDM2 in controlling the bivalent domain inG0.
PRDM2 proteins interact with EZH2
The control of EZH2 association at the PRE by PRDM2
suggests a possible interaction of these two chromatin pro-
teins. To determine if PRDM2directly interacts with EZH2,
we employed pull down assays. Biotin-tagged mRIZ1 or
mRIZ2 were expressed in HEK cells, pulled down us-
ing streptavidin-conjugated beads, followed by immuno-
blotting for EZH2 or a control protein (GAPDH). Inter-
estingly, both isoforms were specifically found in complexes
containing the 85 kD EZH2 protein (Figure 6I). Since the
shRNA targets both isoforms, eitherRIZ1 orRIZ2 or both,
might be involved in limiting the deposition of H3K27
marks on theCCNA2PRE-like element, perhaps by seques-
tering EZH2. Taken together, our observations provide evi-
dence for a PRDM2-dependent mechanism that maintains
CCNA2 in a poised state in G0, by maintaining a balance
of EZH1 and EZH2 at a newly identified PRE-like element.
Our findings establish PRDM2 as a global regulator of
the quiescent state (Figure 7A), where it controls the choice
between alternate forms of arrest. As exemplified by analy-
sis of CCNA2, PRDM2 may maintain regulatory nodes in
an epigenetic state that is repressed but poised for activa-
tion through control of histone methylation, via regulation
of the PRC2 complex (Figure 7B).
DISCUSSION
In this study, we reveal the role of an epigenetic regula-
tor PRDM2/RIZ in cellular quiescence. We show expres-
sion of this tumor suppressor gene in presumptive mus-
cle SCs in vivo and ex vivo on isolated myofibers. Induc-
tion during reversible G0 in mouse and human MBs, mul-
tipotent human MSC and fibroblasts in culture suggests
that PRDM2 may play a role in a common quiescence-
induced program, but our studies have focused on its role
in muscle cell quiescence. We demonstrate that in C2C12
MB, PRDM2 plays a G0-specific repressive role targeting
MyoG, a control hub for muscle differentiation. We pro-
vide evidence that PRDM2 coordinates a genome-wide pro-
gram controlling >1400 transcripts and associating with
>4000 promoters, 55% of which are also marked with re-
pressive H3K9me2 marks. We establish that PRDM2 is a
global repressor of myogenesis in G0 and targets the key
differentiation regulator Myogenin, but also networks both
upstream and downstream of MyoG. We also show that in
G0, PRDM2 preserves expression of stem cell factors and
prevents silencing of cell cycle genes. Finally, we uncover a
new mechanism by which PRDM2 orchestrates control of
CCNA2 in G0, by targeting a quiescence-specific bivalent
domain via regulation of the PRC2 complex. Our findings
support a model for active epigenetic regulation of the qui-
escent state inmuscle cells, where a single regulator PRDM2
coordinates repression of differentiation with protection of
cell cycle and stem cell regulators, to preserve reversibility
of arrest.
PRDM2 is not required for arrest per se but controls the type
of arrest program
As a known tumor suppressor, reduced PRDM2 may be
expected to enhance proliferation. However, knockdown
of PRDM2 did not activate cell division and even led to
hyper-suppression of cell cycle gene expression, while over-
expression of either RIZ1 or two isoform suppressed both
proliferation and differentiation (Figure 1). Together, these
results indicate that in myoblasts, PRDM2 is not required
for arrest per se, but for entry into undifferentiated re-
versible G0, and in its absence, cells enter differentiation-
associated terminal arrest. The bifurcation of arrest pro-
grams appears to be regulated by the Notch pathway, since
G0 fibroblasts enter senescence-associated terminal arrest
when depleted of the Notch target repressor Hes1, (60),
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Figure 7. Model showing PRDM2 as a master regulator of quiescence––regulation of CCNA2 poising in reversible arrest via PRC2 dependent bivalent
domain. (A) PRDM2 choreographs a genome-wide program to keep quiescent cells in a poised state by repressing myogenic networks to prevent differ-
entiation (left), inducing/maintaining myogenic specification factors (right) and preserving reversibility of the cell cycle program via control of balanced
methylation at a newly defined element in CCNA2 intron (center). Knockdown of PRDM2 subverts the quiescence program towards differentiation-
coupled irreversible arrest. (B) PRDM2 prevents PRC2-mediated silencing of CCNA2 by sequestering EZH2 and preventing H3K27me3 accumulation
at the CCNA2 PRE-like element. Thereby, G0 cells are held in suspended animation, poised to return to active proliferation, with a subsequent option
to differentiate if conditions are conducive. PRDM2 knockdown permits EZH2 to accumulate at the PRE, leading to increased H3K27me3, silencing
CCNA2 and diverting quiescence toward differentiation.
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while muscle SCs null for Notch effector RBPJ are di-
verted to differentiation-associated terminal arrest (9,61).
Our findings implicate PRDM2 in control of this regulatory
node. Interestingly, promoters of two Notch pathway genes
(Notch1, Hey1) are both bound by PRDM2 and deregu-
lated in the PRDM2 knockdown cells.
Permanent arrest of MTs is preserved by an Rb-
controlled tumor suppressive network (26,62,63). By re-
cruiting PRC2, Rb silences cell cycle genes and maintains
terminal arrest (64). Intriguingly, PRDM2 was identified
as an Rb-interacting protein (65), and we find it also asso-
ciates with the Rb promoter. Thus, in muscle, while Rb or-
chestrates irreversible arrest (66), PRDM2 plays a key role
in reversible arrest, perhaps by negating Rb. Interestingly,
PRDM2 also associated with promoters of E2Fs (E2F6 and
E2F7, Supplementary Table S5) that induce/maintain qui-
escence along with p130 (27), suggesting a complex balanc-
ing mechanism. For example, E2F6 participates in distinct
activating and repressive chromatin complexes in G0 versus
cycling NIH3T3 cells. In G0 MB, PRDM2 associates with
the E2F6 promoter and E2F6 expression is de-repressed
1.8-fold in PRDM2sh MB. Regulation of the quiescence-
regulating E2F factors supports a role for PRDM2 in
G0. Of 196 E2F target genes (http://bioinfo-out.curie.fr/
projects/rbpathway), 44 genes (22%) were also bound by
PRDM2 in G0, including core components of PRC2 silenc-
ing complex––EED, EZH2, YY1, SUZ12. It is tempting to
speculate that the overlap of PRDM2 targets with those of
quiescence-associated E2F factors may contribute to inter-
play with the Rb-E2F network.
PRDM2 targets a key differentiation control hub
MyoG is activated early in myogenesis by a chromatin
network recruited by MyoD and Meis/Pbx (23); other
epigenetic factors (Suv39h1, EZH2, YY1) repress MyoG
in MB (24). A consensus PRDM2 binding motif in the
MyoG promoter (Supplementary Figure S2) shows in-
creased PRDM2 association in G0 (Figure 3), corre-
lates with increased MyoG promoter activity, and reduced
H3K9me2 in PRDMsh MBs. In cycling MBs, Suv39h re-
presses MyoG expression (25). Conceivably, in G0 MBs,
PRDM2 may augment/replace Suv39h to repress MyoG
and also differentiation.
PRDM2 is a fail-safe repressor of myogenesis in quiescence
Myogenin is a key control point in skeletalmuscle differenti-
ation, as evidenced by the presence of determinedmyoblasts
but absence of differentiated myofibers in MyoG−/− mice
(67). Thus, PRDM2’s repression ofMyoGalonemay be suf-
ficient to repress differentiation in G0. However, the finding
that PRDM2 is associated with a number of muscle-specific
promoters, many of which are deregulated in the knock-
down cells, is suggestive of a wider role. Of the few reported
targets of PRDM2, the IGF1 promoter is directly repressed
viaH3K9me2 in leukemic cells (39). IGF1 and IGF2 signal-
ing promote myogenesis, and in G0 MBs, PRDM2 knock-
down induces IGF2, suggesting that control of this pathway
contributes to repression of differentiation. PRDM2 asso-
ciates with promoters of 27% of genes in the IGF signaling
pathway, >50% of which are marked by H3K9me2.
PRDM2 also associates with a spectrum of muscle-
specific promoters, from transcription factors (MyoG,
MEF2c, MyoD, Foxo1), to cytoskeletal elements (myosins,
troponin, tropomyosin). Many sarcomeric components
were co-associated with PRDM2 and repressive H3K9me2
in G0. PRDM2 may not only target networks at the level
of MyoG, but also upstream and downstream, indicating
a fail-safe repression of differentiation in G0. Thus, the my-
oblast quiescence programmay rely on dominant epigenetic
repression of muscle genes, coordinated by factors such as
PRDM2.
Interestingly, several neurogenic genes involved in neu-
ral fate and signaling were also co-marked by PRDM2 and
H3K9me2 and de-regulated by PRDM2 knockdown, sug-
gesting broad suppression of differentiation programs.
PRDM2 protects cell cycle and stem cell regulatory genes in
G0
In G0, both cell cycle genes and muscle genes are normally
repressed. However, in PRDM2sh MB, cell cycle genes are
hyper-repressed while myogenic genes are hyper-activated
(Figure 3J), indicating a switch from undifferentiated ar-
rest to differentiated arrest. In MT, cell cycle genes are per-
manently silenced (transcriptionally repressed, H3K27me3
marked) via PRC2 (64), which is not seen inG0 MB.Knock-
down of PRDM2 altered CCNA2 promoter marking to
that typical of irreversible exit: increased H3K27me3, re-
duced H3K4me3 (Figure 6). In addition to cyclin A2, both
PRDM2 and H3K9me2 were enriched at promoters of cy-
clins A1, B, D, E, G, I, J and L in G0 (GEO GSE58676).
Although our analysis of the CCND1 promoter did not re-
veal strong bivalent marking (Supplementary Figure S7),
expression of cyclins D, E and B was also suppressed in the
PRDM2 knockdown (Figure 3). Thus, it is conceivable that
while repressive, sustained H3K9 methylation by PRDM2
(or other HMTs) may also maintain a basal activity or pois-
ing of other cell cycle genes in G0, protecting these key
targets from permanent silencing, possibly by modulating
PRC2 activity (Figures 5 and 6).
Intriguingly, PRDM2 also associates with promoters
of stem cell and pluripotency markers (Figure 4G) such
as HSC marker c-kit, pluripotency factor Oct4, and
self-renewal factor Jmjd1a (68). PRDM2 also regulates
muscle determinant Myf5, and Pax7 (Figure 3J), a SC
survival/specification factor that recruits remodeling com-
plexes to muscle promoters (69). PRDM2 knockdown in-
hibits expression of these SC genes, consistent with a role in
maintaining their expression in G0. Association of PRDM2
with promoters of PRC2 members in G0 suggests coordi-
nated control of cell cycle and stem cell genes. PRC2 me-
diates repression of developmental genes, is required for
maintenance of potency and self-renewal (70) and condi-
tional removal of EZH2 in Pax7+ SC leads to loss of self-
renewal (71). Taken together with the reduced colony form-
ing ability of PRDM2sh cells, these observations under-
score a link between quiescence and self-renewal.
Although the methyltransferase activity of PRDM2 is
well established (38,72) and the crystal structure of its SET
domain determined (73), the specificity for histonemethyla-
tion state has not been unambiguously established. In vitro
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HMT assays of transfected Hela cells (74) and C2C12 cells
(Figure 2I) clearly indicate that RIZ1 can transfer methyl
groups to H3K9. While the relationship of PRDM2 occu-
pancy to H3K9me2 marks is correlative, our global analy-
sis revealing their widespread co-association may indicate a
role for this chromatin factor in mediating this modification
directly or indirectly.
PRDM2 regulates association of PRC2 at a novel CCNA2
regulatory element
Unexpectedly for a tumor suppressor, PRDM2 preserves
basal cyclin expression in G0. We therefore explored the
mechanism by which this epigenetic regulator may keep
genes poised while repressed. Bivalent chromatin domains
(dually methylated at H3K43Me and H3K273Me) in fate-
specification genes in ESC are associated with poising and
these domains resolve to exhibit unique histone marks dur-
ing lineage commitment (29). Bivalent marking has been
recently demonstrated in ASCs (75) including muscle SCs
(32), suggesting conserved mechanisms of poising. Intrigu-
ingly, our findings suggest that such epigenetic mechanisms
are preserved even in the C2C12 cell line which was origi-
nally derived from adult SCs (76).
We chose CCNA2 gene to probe the PRDM2-regulated
poising control mechanism since PRDM2 was earlier re-
ported to interact with Rb and CCNA2 is a key target of
the Rb-E2F-PRC2 axis. Our finding that PRDM2 asso-
ciates with many E2F targets and key PRC2 genes under-
scored these links. PRC2-mediated Cyc A regulation in flies
suggested the potential for conserved regulatory mecha-
nisms. Our analysis uncovered newmechanisms controlling
CCNA2: (i) CCNA2 locus undergoes cell cycle-dependent
epigenetic modulation at a newly defined intronic element
distinct from the well-known CCRE, (ii) the intronic el-
ement has repressive activity and binds a unique combi-
nation of PRC2 members specifically in G0, suggesting
PRE-like function, (iii) bivalent histone marks at the pu-
tative PRE are converted to activation marks in cycling
MBs where CCNA2 is expressed and silencing marks in
MTs where CCNA2 is repressed, (iv) bivalent marks as well
PRC2 association are lost in PRDM2sh cells. Importantly,
using re-ChIP analysis, we also demonstrate that the novel
element is truly bivalent, and cannot be attributed to cellu-
lar heterogeneity.
Interaction of PRDM2 and EZH2 proteins in muscle cells
Rather than mediating de novo gene silencing, evidence sug-
gests that PRC2 plays a major role to maintain the repres-
sive status of its targets (77). We, and others, have shown
that repression of CCNA2 during G0 in myoblasts is medi-
ated byBrm/Brg, CCRE-binding repressors, under the con-
trol of a Trx protein MLL5 (11,48). Our new findings show
that both isoforms of PRDM2 interact with EZH2, whose
association at the PRE (downstream of the CCRE) is in-
creased in PRDM2RNAi cells along with hyper-repression
of CCNA2. Of the two H3K27 methyl transferases in the
PRC2 complex, EZH2 is reported to be a much more ac-
tive enzyme than EZH1 (78). The balanced enrichment
of EZH1/EZH2 association with the PRE in G0 (Figure
6) and the shift to greater EZH2 enrichment in PRDM2
RNAi cells (reflecting the normal MT pattern), are consis-
tent with hyper-repression of CCNA2. Our findings suggest
a model where association of MLL5 and Brm/Brg at the
CCRE during entry into quiescence, may initiate repression
of CCNA2, while presence of PRDM2 at the PREmay pre-
vent silencing by limiting association of EZH2, maintain-
ing the poised state and competence for reactivation by mi-
togen stimulation. Establishing the timing of these events
will be of importance in understanding the relative contri-
butions of each of these factors. Together with our earlier
findings, our observations point to CCNA2 as a regulatory
node in quiescence targeted by MLL5, Brm/Brg, PRDM2
and PRC2.
PRDM2 may define a quiescence program
PRDMproteins have been implicated asmolecular switches
in cell fate choices. PRDM1 mediates selection of slow ver-
sus fast skeletal muscle (79), PRDM6 between differenti-
ation and proliferation in smooth muscle (80), PRDM14
between self-renewal and lineage commitment in ESC (81)
and PGC (82), and PRDM16 between brown fat and skele-
tal muscle (83). Our results suggest that PRDM2 regulates a
switch between reversible versus irreversible arrest in mus-
cle cells, by regulating association of the PRC complex at
a novel element in a key S-phase control gene, CCNA2
(Figure 7). Interestingly, many PRDM2 bound genes are
reported to be targets of PRDM14, a regulator of ESC
pluripotency (81), suggestive of a potential role in self-
renewal (Supplementary Figure S9). Not all PRDM family
members have intrinsic histone modification activity (84),
and may function via their interacting partners. While the
two PRDM2 isoforms differ in their intrinsic HMT activity,
they are both able to interact with pRb (35,40) and EZH2
(Figure 6). We speculate that the two isoforms may com-
pete for these partners, which may control the extent of re-
pressive marking of specific loci. Further, the complexes in
which PRDM2 is found may differ at myogenic and cell cy-
cle promoters, which may explain the differential regulation
of these programs by a single regulator.
CONCLUSIONS
In summary, we provide evidence that PRDM2 is required
for maintaining quiescence not only by preventing inap-
propriate differentiation but also by protecting cell cy-
cle and stem cell genes from silencing. We propose that
PRDM2/RIZ choreographs a genome-wide quiescence-
associated program that maintains cells in a poised state
and by holding two antagonistic programs in abeyance, pre-
serves the option for alternate fates- a return to active pro-
liferation or differentiation.
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